<DOC>
	<DOC>NCT02553798</DOC>
	<brief_summary>This is an open-label, long-term safety study of DRM04 Topical Wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.</brief_summary>
	<brief_title>Long-term Safety Study of DRM04 in Subjects With Primary Axillary Hyperhidrosis</brief_title>
	<detailed_description>Safety will be assessed through adverse events, blood and urine laboratory tests, physical examination, pulse and blood pressure. Local skin reactions will be assessed including burning/stinging, pruritus, edema, erythema, dryness and scaling.</detailed_description>
	<mesh_term>Hyperhidrosis</mesh_term>
	<criteria>Completed Day 28 of either the DRM04HH04 or DRM04HH05 study with at least 80% treatment compliance Male or females Subject has a clinically significant abnormality on physical exam, vital signs or ECG at the Week 4 visit of DRM04HH04 or DRM04HH05 study that would make further treatment with DRM04 contraindicated Male with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy Any other condition which, in the judgement of the Investigator, would put the subject at unacceptable risk for participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>